BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12778069)

  • 1. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
    Edmunds SC; Cree IA; Dí Nícolantonío F; Hungerford JL; Hurren JS; Kelsell DP
    Br J Cancer; 2003 May; 88(9):1403-5. PubMed ID: 12778069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutations are detectable in conjunctival but not uveal melanomas.
    Spendlove HE; Damato BE; Humphreys J; Barker KT; Hiscott PS; Houlston RS
    Melanoma Res; 2004 Dec; 14(6):449-52. PubMed ID: 15577314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
    Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
    J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of BRAF mutation in primary uveal melanoma.
    Cohen Y; Goldenberg-Cohen N; Parrella P; Chowers I; Merbs SL; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2876-8. PubMed ID: 12824225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
    Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
    Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutations in conjunctival melanoma.
    Gear H; Williams H; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
    Weber A; Hengge UR; Urbanik D; Markwart A; Mirmohammadsaegh A; Reichel MB; Wittekind C; Wiedemann P; Tannapfel A
    Lab Invest; 2003 Dec; 83(12):1771-6. PubMed ID: 14691295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of SF3B1 R625 mutations in cutaneous melanoma.
    Schilling B; Bielefeld N; Sucker A; Hillen U; Zimmer L; Schadendorf D; Zeschnigk M; Griewank KG
    Diagn Pathol; 2013 May; 8():87. PubMed ID: 23694694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T1799A point mutation is present in posterior uveal melanoma.
    Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
    Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
    Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
    Shinozaki M; Fujimoto A; Morton DL; Hoon DS
    Clin Cancer Res; 2004 Mar; 10(5):1753-7. PubMed ID: 15014028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
    Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
    Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T1799A BRAF mutation is present in iris melanoma.
    Henriquez F; Janssen C; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of V599E BRAF mutations in desmoplastic melanomas.
    Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
    Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
    Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
    Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.